C4 Therapeutics (NASDAQ:CCCC) Stock Price Expected to Rise, Brookline Capital Acquisition Analyst Says

C4 Therapeutics (NASDAQ:CCCC) had its price target hoisted by research analysts at Brookline Capital Acquisition from $20.00 to $30.00 in a research note issued to investors on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the stock.

CCCC has been the subject of a number of other research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of C4 Therapeutics in a research report on Wednesday, January 21st. Barclays lowered their target price on C4 Therapeutics from $10.00 to $5.00 and set an “overweight” rating on the stock in a research report on Wednesday, December 17th. Finally, TD Cowen began coverage on C4 Therapeutics in a research report on Tuesday, December 2nd. They issued a “buy” rating for the company. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $11.80.

C4 Therapeutics Trading Up 2.5%

NASDAQ CCCC traded up $0.06 during trading hours on Monday, hitting $2.22. 999,602 shares of the company’s stock traded hands, compared to its average volume of 1,326,316. C4 Therapeutics has a 52 week low of $1.09 and a 52 week high of $3.65. The firm has a market capitalization of $214.66 million, a P/E ratio of -1.32 and a beta of 2.96. The business’s fifty day moving average price is $2.04 and its two-hundred day moving average price is $2.35.

Hedge Funds Weigh In On C4 Therapeutics

Several large investors have recently made changes to their positions in CCCC. Virtu Financial LLC purchased a new stake in shares of C4 Therapeutics during the fourth quarter worth about $39,000. Invesco Ltd. grew its holdings in C4 Therapeutics by 39.9% during the 4th quarter. Invesco Ltd. now owns 268,350 shares of the company’s stock valued at $513,000 after buying an additional 76,530 shares in the last quarter. Quadrature Capital Ltd purchased a new stake in C4 Therapeutics during the 4th quarter valued at approximately $254,000. Man Group plc raised its position in shares of C4 Therapeutics by 72.9% during the fourth quarter. Man Group plc now owns 156,098 shares of the company’s stock valued at $298,000 after buying an additional 65,820 shares during the last quarter. Finally, Engineers Gate Manager LP lifted its holdings in shares of C4 Therapeutics by 49.9% in the fourth quarter. Engineers Gate Manager LP now owns 24,416 shares of the company’s stock worth $47,000 after buying an additional 8,130 shares in the last quarter. 78.81% of the stock is currently owned by hedge funds and other institutional investors.

About C4 Therapeutics

C4 Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted protein degraders. Utilizing its proprietary Controlled Inducible Degradation (CiD) platform, the company seeks to eliminate disease-causing proteins by harnessing the body’s natural protein disposal machinery. This approach aims to address a wide range of oncology and immuno-oncology indications by targeting proteins that have historically been difficult to inhibit with traditional small molecules or antibodies.

The company’s pipeline includes multiple small-molecule degrader candidates advancing through preclinical and clinical stages.